MX9802372A - N-heterociclos condensados, sustituidos con benciloxi, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina. - Google Patents

N-heterociclos condensados, sustituidos con benciloxi, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina.

Info

Publication number
MX9802372A
MX9802372A MX9802372A MX9802372A MX9802372A MX 9802372 A MX9802372 A MX 9802372A MX 9802372 A MX9802372 A MX 9802372A MX 9802372 A MX9802372 A MX 9802372A MX 9802372 A MX9802372 A MX 9802372A
Authority
MX
Mexico
Prior art keywords
employment
preparation
bradyquinine
heterocycles
benzyloxy
Prior art date
Application number
MX9802372A
Other languages
English (en)
Other versions
MXPA98002372A (es
Inventor
Holger Heitsch
Adalbert Wagner
Klaus Wirth
Bernward Scholkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX9802372A publication Critical patent/MX9802372A/es
Publication of MXPA98002372A publication Critical patent/MXPA98002372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son objeto de la invencion compuestos de la formula (I), en la que B, d, R1 y R2 tienen los significados indicados en las reivindicaciones, un procesamiento para su reparacion y su empleo como agente curativo y terapéutico para el tratamiento y la prevencion de la cirrosis hepática o de la enfermedad de Alzheimer.
MXPA/A/1998/002372A 1997-03-27 1998-03-26 N-heterociclos condensados, sustituidos con benciloxi, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina MXPA98002372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19712960A DE19712960A1 (de) 1997-03-27 1997-03-27 Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
DE19712960.9 1997-03-27

Publications (2)

Publication Number Publication Date
MX9802372A true MX9802372A (es) 1998-09-30
MXPA98002372A MXPA98002372A (es) 1998-11-16

Family

ID=

Also Published As

Publication number Publication date
BR9801132A (pt) 2000-03-21
TR199800543A2 (xx) 1998-10-21
KR19980080757A (ko) 1998-11-25
AU5965298A (en) 1998-10-01
ES2223090T3 (es) 2005-02-16
HUP9800649A2 (hu) 1998-12-28
JPH10279563A (ja) 1998-10-20
NO981383D0 (no) 1998-03-26
HU9800649D0 (en) 1998-05-28
EP0867432A3 (de) 1998-10-14
US6211196B1 (en) 2001-04-03
EP0867432B1 (de) 2004-06-09
PL325597A1 (en) 1998-09-28
CN1194978A (zh) 1998-10-07
DE19712960A1 (de) 1998-10-01
HUP9800649A3 (en) 1999-01-28
CA2232499A1 (en) 1998-09-27
CZ91498A3 (cs) 1998-10-14
ATE268759T1 (de) 2004-06-15
EP0867432A2 (de) 1998-09-30
NO981383L (no) 1998-09-28
DE59811526D1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
NZ522326A (en) Adenosine A2A receptor antagonists
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
EP1149583A3 (en) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
GB0225475D0 (en) Therapeutic agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
JO2371B1 (en) 4-phenyl-pyridine derivatives
BG104727A (en) Pharmaceutical composition of topiramate
DE60006280D1 (de) Beta 2 -adrenergische rezeptor-agonisten
GB0025173D0 (en) Therapeutic agents
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
MXPA03002911A (es) Compuestos quimicos.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BG105256A (en) Muscarinic agonists and antagonists
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
BR9801132A (pt) N-heterociclos fundidos, substituìdos com benzilóxi, processo para a sua preparação e seu uso como antagonistas de receptor de bradiquinina.
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
AP2001002369A0 (en) Pharmaceutical complex.
BR0005319A (pt) Tratamento combinado para depressão e ansiedade